CADTH | Evidence Driven
CADTH | Evidence Driven

Jakavi for myelofibrosis

Details

Files
Generic Name:
Ruxolitinib
Project Status:
Complete
Therapeutic Area:
Myelofibrosis
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Jakavi
Project Line:
Reimbursement Review
Project Number:
PC0012-000
Strength:
5mg, 15mg, and 20mg
Tumour Type:
Other
Indications:
Myelofibrosis
Funding Request:
For the treatment of patients with myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.
Review Status:
Complete
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Ruxolitinib (Jakavi) for myelofibrosis - pERC Final Recommendation Final Recommendation January 14, 2013 View PDF
Ruxolitinib (Jakavi) for myelofibrosis - Final Clinical Guidance Report Guidance Reports January 14, 2013 View PDF
Ruxolitinib (Jakavi) for myelofibrosis - Final Economic Guidance Report Guidance Reports January 14, 2013 View PDF
Ruxolitinib (Jakavi) for myelofibrosis - pERC Initial Recommendation Initial Recommendation November 1, 2012 View PDF
Ruxolitinib (Jakavi) for myelofibrosis - PAG Feedback on Initial Recommendation Feedback January 14, 2013 View PDF
Ruxolitinib (Jakavi) for myelofibrosis - Manufacturer (Novartis) Feedback on Initial Recommendation Feedback January 14, 2013 View PDF
Ruxolitinib (Jakavi) for myelofibrosis - Patient Advocacy Group (CML) Feedback on Initial Recommendation Feedback January 14, 2013 View PDF
Ruxolitinib (Jakavi) for myelofibrosis - Patient Advocacy Group (CML) COI Declarations Feedback January 14, 2013 View PDF
Ruxolitinib (Jakavi) for myelofibrosis - Patient Advocacy Group (CPMNN) Feedback on Initial Recommendation Feedback January 14, 2013 View PDF
Ruxolitinib (Jakavi) for myelofibrosis - Patient Advocacy Group (CPMNN) COI Declarations Feedback January 14, 2013 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : January 30, 2013